Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q4 FY2024 Earnings Presentation
19 slides from Aurobindo Pharma's earnings presentation, May 25, 2024
Slide 1: Letter to stock exchanges: Investor / Analysts Presentation
May 25, 2024 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, MUMBAI -400 051 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. AUROPHARMA Company Cod
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q4FY24
Aurobindo Pharma Limited Earnings Presentation Q4FY24
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Table of Content
Table of Content 04 Q4FY24 Business & Financial Highlights 10 Update on biosimilars 12 Financial Summary 13 15 Filings Snapshot 3
Slide 5: Q4FY24 Business & Financial Highlights
Q4FY24 Business & Financial Highlights 4
Slide 6: Quarterly Performance – Q4 FY24
Quarterly Performance – Q4 FY24 Revenue (Rs Crore) US Revenue excluding Puerto Rico (US$ Mn) 409 451 7,580 432 7,352 382 7,219 355 359 6,851 6,407 6,473 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 EBITDA (Rs Crore) Net Debt to Equity 1,601 1,687 -0.01 1,403 -0
Slide 7: Consolidated Financial & Business Highlights – Q4 FY24
Consolidated Financial & Business Highlights – Q4 FY24 Revenue from operations at Rs 7,580 Crore, an increase of 17.1% YoY | US revenues (excl. Puerto Rico) at US$ 432 Mn EBITDA before Forex and Other income at Rs 1,687 Crore | EBITDA margin is at 22.3% Net Profit after minority interest is Rs 909 C
Slide 8: Consolidated Operational Performance
Consolidated Operational Performance Rs Crore Q4FY24 Q4FY23 Y-o-Y (%) Q3FY24 Q-o-Q (%) FY24 FY23 Y-o-Y (%) USA** 3,588 2,951 21.6% 3,756 -4.5% 13,867 11,227 23.5% Europe 1,832 1,660 10.4% 1,728 6.0% 7,166 6,426 11.5% Growth Markets* 852 570 49.5% 627 35.9% 2,517 1,951 29.0% ARV 238 181 31.5% 179 32.
Slide 9: US Formulations Business Performance Highlights (Excluding Puerto Rico)
US Formulations Business Performance Highlights (Excluding Puerto Rico) Revenue (US$ Mn) Commentary 500 451 432 • US revenue in Q4FY24 increased by 20.4% YoY and decreased 400 359 by 4.2% QoQ to USD 432 Mn, accounting for 47.3% of 300 consolidated revenue 200 100 • Q4FY24: Specialty & Injectables re
Slide 10: Europe, Growth Markets, ARV, API Business Revenues & Performance Highlights
Europe, Growth Markets, ARV, API Business Revenues & Performance Highlights Europe (EUR Mn) Growth Markets (US$ Mn) ARV (US$ Mn) API (Rs Crore) 1,017 1,022 1,019 103 203 188 193 75 69 29 22 22 Q4FY23 Q3FY24 Q4FY24 Q4FY23 Q3FY24 Q4FY24 Q4FY23 Q3FY24 Q4FY24 Q4FY23 Q3FY24 Q4FY24 Growth Markets posted r
Slide 11: Update on Biosimilars
Update on Biosimilars 10
Slide 12: Advancing our Oncology and Immunology Biosimilar Programs - Biologics
Advancing our Oncology and Immunology Biosimilar Programs -Biologics • CuraTeQ Biologics is a wholly owned subsidiary of Aurobindo Pharma Ltd • Our business strategy primarily focuses on developing Oncology and Immunology biosimilars • Our broader pipeline of 14 biosimilars positions CuraTeQ uniquel
Slide 13: Financial Summary
Financial Summary 12
Slide 14: Consolidated Profit & Loss Statement (as reported)
Consolidated Profit & Loss Statement (as reported) YoY Chg. QoQ Chg. YoY Chg. Rs Cr Q4FY24 Q4FY23 Q3FY24 FY24 FY23 (%) (%) (%) Revenue from operations 7,580 6,473 17.1% 7,352 3.1% 29,002 24,855 16.7% Gross Profit 4,519 3,542 27.6% 4,201 7.6% 16,399 13,562 20.9% Gross Margin 59.6% 54.7% 490 bps 57.1%
Slide 15: Debt profile
Debt profile Gross debt (US$ Mn) Debt as on (INR Cr) Mar-21 Mar-22 Mar-23 Mar-24 Closing Rate (INR/USD) 73.110 75.793 82.170 83.405 674 313 592 645 752 815 758 Fx Loan restated in INR 4,929 2,223 4,638 3,994 Rupee Loan 44 150 224 2,234 Gross Debt 4,972 2,373 4,862 6,318 110 206 251 256 75 182 Cash B
Slide 16: Filing Snapshot
Filing Snapshot 15
Slide 17: US ANDA Filings Snapshot as on 31st March 2024
US ANDA Filings Snapshot as on 31st March 2024 ANDA Filings Addressable Market Therapy ANDAs Size (US$ Bn)^ 658 CNS 148 27.2 Aurobindo (Excl. Specialty & 700 600 Specialty & Injectables 300 600 489 ARV 29 0.5 500 250 500 200 169 Injectables) 400 400 150 45.2 300 CVS 120 300 145 118 54 200 100 200 10
Slide 18: Global regulatory filing Details
Global regulatory filing Details As at As at As at As at As at As at As at As at As at Category Geography Approvals Mar 16 Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 Mar 22 Mar 23 Mar 24 US* 398 429 478 541 586 639 727^ 774^ 830 FA: 658, TA:27 Europe** 2,224 2,521 2,848 3,003 3,214 3,374 3,580 3,751 3,642 2
Slide 19: Thank You
Digitally signed by BADDIGAM ADI REDDY Date: 2024.05.25 19:18:14 +05'30' Thank You For more information, contact: ir@aurobindo.com; cc@aurobindo.com Investor Relations | Corporate Communications www.aurobindo.com +91 40 6672 1551 | 6672 5005 18